Sonoma Pharmaceuticals (SNOA) Competitors $2.99 +0.15 (+5.28%) (As of 01:52 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SNOA vs. APRE, TXMD, AKTX, MTEX, INAB, NERV, BGXX, NRXP, KZIA, and PMCBShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Aprea Therapeutics (APRE), TherapeuticsMD (TXMD), Akari Therapeutics (AKTX), Mannatech (MTEX), IN8bio (INAB), Minerva Neurosciences (NERV), Bright Green (BGXX), NRx Pharmaceuticals (NRXP), Kazia Therapeutics (KZIA), and PharmaCyte Biotech (PMCB). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Aprea Therapeutics TherapeuticsMD Akari Therapeutics Mannatech IN8bio Minerva Neurosciences Bright Green NRx Pharmaceuticals Kazia Therapeutics PharmaCyte Biotech Aprea Therapeutics (NASDAQ:APRE) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership. Which has more volatility & risk, APRE or SNOA? Aprea Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Which has better earnings and valuation, APRE or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$580K27.34-$14.29M-$2.81-1.04Sonoma Pharmaceuticals$12.73M0.31-$4.84M-$4.99-0.60 Do institutionals and insiders hold more shares of APRE or SNOA? 34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 12.8% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to APRE or SNOA? In the previous week, Aprea Therapeutics had 5 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 5 mentions for Aprea Therapeutics and 0 mentions for Sonoma Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 0.64 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aprea Therapeutics Positive Sonoma Pharmaceuticals Neutral Does the MarketBeat Community prefer APRE or SNOA? Sonoma Pharmaceuticals received 163 more outperform votes than Aprea Therapeutics when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 55.79% of users gave Aprea Therapeutics an outperform vote. CompanyUnderperformOutperformAprea TherapeuticsOutperform Votes5355.79% Underperform Votes4244.21% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Do analysts recommend APRE or SNOA? Aprea Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 430.82%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aprea Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is APRE or SNOA more profitable? Sonoma Pharmaceuticals has a net margin of -27.21% compared to Aprea Therapeutics' net margin of -1,029.50%. Aprea Therapeutics' return on equity of -57.86% beat Sonoma Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,029.50% -57.86% -47.94% Sonoma Pharmaceuticals -27.21%-59.58%-24.33% SummaryAprea Therapeutics beats Sonoma Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.01M$4.48B$5.10B$8.84BDividend YieldN/A36.79%5.04%4.07%P/E Ratio-0.6014.3295.1214.22Price / Sales0.3144.111,217.3088.42Price / CashN/A52.2739.4936.27Price / Book0.755.836.976.37Net Income-$4.84M$13.76M$118.73M$225.56M7 Day Performance15.89%-0.08%-1.22%-0.02%1 Month Performance0.67%1.51%-3.07%2.04%1 Year Performance1,562.96%51.75%32.52%28.00% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.839 of 5 stars$2.99+5.3%N/A+1,381.5%$4.01M$12.73M-0.60180APREAprea Therapeutics3.3831 of 5 stars$2.92-3.0%$15.50+430.8%-22.4%$15.86M$580,000.000.007Analyst ForecastAnalyst RevisionGap DownTXMDTherapeuticsMD0.6657 of 5 stars$1.37+2.2%N/A-54.1%$15.80M$1.30M0.00420Analyst ForecastAKTXAkari TherapeuticsN/A$1.30-11.6%N/A-55.0%$15.80MN/A0.009Analyst ForecastNews CoverageHigh Trading VolumeMTEXMannatech0.936 of 5 stars$8.40+4.3%N/A-15.5%$15.79M$131.96M0.00250Analyst ForecastGap UpHigh Trading VolumeINABIN8bio2.7424 of 5 stars$0.34+4.2%$7.75+2,213.4%-62.8%$15.68MN/A0.0020NERVMinerva Neurosciences2.3494 of 5 stars$2.21+4.2%$5.00+126.2%-57.1%$15.45MN/A-4.829Analyst ForecastBGXXBright GreenN/A$0.08-6.7%N/A-78.4%$15.18MN/A-1.422News CoverageGap DownNRXPNRx Pharmaceuticals1.9932 of 5 stars$1.210.0%$31.50+2,503.5%-96.1%$14.63MN/A0.002KZIAKazia Therapeutics1.8779 of 5 stars$5.49-2.1%$20.00+264.3%-26.9%$14.49M$1.51M0.0012PMCBPharmaCyte Biotech0.6454 of 5 stars$1.79+4.1%N/A-21.1%$13.75MN/A2.612 Related Companies and Tools Related Companies Aprea Therapeutics Competitors TherapeuticsMD Competitors Akari Therapeutics Competitors Mannatech Competitors IN8bio Competitors Minerva Neurosciences Competitors Bright Green Competitors NRx Pharmaceuticals Competitors Kazia Therapeutics Competitors PharmaCyte Biotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNOA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
